Current Environment: Production

Medical Services

Specialties

Programs & Services

Education

Medical School

Harvard Medical School

Boston, MA

Residency

Physician, Cancer and Blood Disorders Center

Boston, MA

Publications

  1. Evaluating Adjuvant Radiation Therapy for Grade 2 Meningioma: A Multi-Institutional Analysis. Neurosurgery. 2025 Apr 29. View Abstract

  2. Impact of brain metastasis size at the time of radiotherapy on local control and radiation necrosis. J Neurooncol. 2025 Apr 15. View Abstract

  3. PD-L1, Tumor Mutational Burden, and Outcomes in NSCLC With Brain Metastases: A Brief Report. JTO Clin Res Rep. 2025 Apr; 6(4):100797. View Abstract

  4. Re-Irradiation Plus Pembrolizumab: A Phase II Study for Patients with Recurrent Glioblastoma. Clin Cancer Res. 2025 Jan 17; 31(2):316-327. View Abstract

  5. Intracranial outcomes following neurosurgical resection in patients with brain metastases secondary to HER2-positive breast cancer versus other subtypes. Breast Cancer Res Treat. 2025 Jan; 209(2):303-314. View Abstract

  6. Progestin-associated meningiomatosis with unusual schwannoma-like morphology. J Neuropathol Exp Neurol. 2024 02 21; 83(3):214-216. View Abstract

  7. Clinical Outcomes Among Patients Treated With Stereotactic Body Radiation Therapy to Femur Metastases for Oligometastatic Disease Control or Reirradiation: Results From a Large Single-Institution Experience. Adv Radiat Oncol. 2024 Apr; 9(4):101439. View Abstract

  8. Re-irradiation of recurrent IDH-wildtype glioblastoma in the bevacizumab and immunotherapy era: Target delineation, outcomes and patterns of recurrence. Clin Transl Radiat Oncol. 2024 Jan; 44:100697. View Abstract

  9. Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization. J Clin Oncol. 2023 Dec 20; 41(36):5524-5535. View Abstract

  10. Evaluating hematologic parameters in newly diagnosed and recurrent glioblastoma: Prognostic utility and clinical trial implications of myelosuppression. Neurooncol Adv. 2023 Jan-Dec; 5(1):vdad083. View Abstract

  11. Phase I study of a novel glioblastoma radiation therapy schedule exploiting cell-state plasticity. Neuro Oncol. 2023 06 02; 25(6):1100-1112. View Abstract

  12. Incidence proportion and prognosis of leptomeningeal disease among patients with breast vs. non-breast primaries. Neuro Oncol. 2023 05 04; 25(5):973-983. View Abstract

  13. Comparison of MR-soft tissue based versus biliary stent based alignment for image guidance in pancreatic SBRT. J Appl Clin Med Phys. 2023 Jul; 24(7):e13965. View Abstract

  14. Patient specific distortion detection and mitigation in MR images used for stereotactic radiosurgery. Phys Med Biol. 2022 03 11; 67(6). View Abstract

  15. Magnetic Resonance-Guided Prostate Stereotactic Body Radiation Therapy With Daily Online Plan Adaptation: Results of a Prospective Phase 1 Trial and Supplemental Cohort. Adv Radiat Oncol. 2022 Sep-Oct; 7(5):100934. View Abstract

  16. Intracerebral haemorrhage in patients with brain metastases receiving therapeutic anticoagulation. J Neurol Neurosurg Psychiatry. 2021 Mar 09. View Abstract

  17. Assessment of Simulated SARS-CoV-2 Infection and Mortality Risk Associated With Radiation Therapy Among Patients in 8 Randomized Clinical Trials. JAMA Netw Open. 2021 03 01; 4(3):e213304. View Abstract

  18. Feasibility of hippocampal avoidance whole brain radiation in patients with hippocampal involvement: Data from a prospective study. Med Dosim. 2021 Spring; 46(1):21-28. View Abstract

  19. A Quantitative Framework for Modeling COVID-19 Risk During Adjuvant Therapy Using Published Randomized Trials of Glioblastoma in the Elderly. Neuro Oncol. 2020 Apr 27. View Abstract

  20. Quantifying the impact of surgical decompression on quality of life and identification of factors associated with outcomes in patients with symptomatic metastatic spinal cord compression. J Neurosurg Spine. 2020 08 01; 33(2):237-244. View Abstract

  21. The Current and Evolving Role of Radiation Therapy for Central Nervous System Metastases from Breast Cancer. Curr Oncol Rep. 2019 04 16; 21(6):50. View Abstract

  22. Breast cancer subtype and intracranial recurrence patterns after brain-directed radiation for brain metastases. Breast Cancer Res Treat. 2019 Jul; 176(1):171-179. View Abstract

  23. Local control after brain-directed radiation in patients with cystic versus solid brain metastases. J Neurooncol. 2019 Apr; 142(2):355-363. View Abstract

  24. Neurosurgical Resection and Stereotactic Radiation Versus Stereotactic Radiation Alone in Patients with a Single or Solitary Brain Metastasis. World Neurosurg. 2019 Feb; 122:e1557-e1561. View Abstract

  25. Neurologic Complications of Radiation Therapy. Neurol Clin. 2018 08; 36(3):599-625. View Abstract

  26. Impact of pemetrexed on intracranial disease control and radiation necrosis in patients with brain metastases from non-small cell lung cancer receiving stereotactic radiation. Radiother Oncol. 2018 03; 126(3):511-518. View Abstract

  27. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype. J Natl Cancer Inst. 2017 09 01; 109(9). View Abstract

  28. Leveraging molecular datasets for biomarker-based clinical trial design in glioblastoma. Neuro Oncol. 2017 Jul 01; 19(7):908-917. View Abstract

  29. Gallbladder toxicity and high-dose ablative-intent radiation for liver tumors: Should we constrain the dose? Pract Radiat Oncol. 2017 Sep - Oct; 7(5):e323-e329. View Abstract

  30. Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas. Neuro Oncol. 2017 01; 19(1):109-117. View Abstract

  31. Hypofractionation for Early-Stage Breast Cancer: No More Excuses. JAMA Oncol. 2015 Oct; 1(7):941-2. View Abstract

  32. In Reply to Levra et al. Int J Radiat Oncol Biol Phys. 2015 Sep 01; 93(1):218-9. View Abstract

  33. Prospective assessment of deep inspiration breath-hold using 3-dimensional surface tracking for irradiation of left-sided breast cancer. Pract Radiat Oncol. 2015 Nov-Dec; 5(6):358-65. View Abstract

  34. Whole Lung Irradiation in Adults with Metastatic Ewing Sarcoma: Practice Patterns and Implications for Treatment. Sarcoma. 2015; 2015:591698. View Abstract

  35. Radiotherapy for liver tumors. Hepat Oncol. 2015 Apr; 2(2):133-146. View Abstract

  36. Hypofractionated versus standard radiation therapy with or without temozolomide for older glioblastoma patients. Int J Radiat Oncol Biol Phys. 2015 Jun 01; 92(2):384-9. View Abstract

  37. Outcomes of proton therapy for patients with functional pituitary adenomas. Int J Radiat Oncol Biol Phys. 2014 Nov 01; 90(3):532-9. View Abstract

  38. Radiation therapy for liver tumors: ready for inclusion in guidelines? Oncologist. 2014 Aug; 19(8):868-79. View Abstract

  39. Evaluating the Impact of PSA as a Selection Criteria for Nerve Sparing Radical Prostatectomy in a Screened Cohort. Prostate Cancer. 2014; 2014:395078. View Abstract

  40. Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease. Proc Natl Acad Sci U S A. 2010 Jul 13; 107(28):12617-22. View Abstract

  41. An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. PLoS Med. 2008 Feb; 5(2):e35. View Abstract

  42. A new double-lumen tube adapter. Anesth Analg. 1980 Jul; 59(7):507-8. View Abstract
BESbswy